Long-term study for those who took PBGENE-HBV
Part of Digestive system, Infections clinical trials.
This study follows people who have already received the experimental gene therapy PBGENE-HBV for hepatitis B. It aims to monitor long-term safety and health outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received at least one dose of PBGENE-HBV in a previous clinical trial.
- You or your legal representative must sign a consent form agreeing to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy called PBGENE-HBV for people with chronic hepatitis B who are already on antiviral treatment. The goal is to see if it is safe and can help control the virus.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
This study looks at the genes of people with chronic hepatitis B (HBV) to find why some people's immune cells (B cells and NK cells) stop working properly. The goal is to discover new ways to treat the disease.
This study follows participants with chronic hepatitis B who previously responded to the drug AHB-137. The goal is to track long-term health and safety after their treatment.
This study looks at genetic factors that may help people with chronic hepatitis B achieve a clinical cure when treated with long-acting interferon. It aims to find out why some patients respond better than others.
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
Hear when a new Chronic HBV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.